Else Nutrition's Q3 revenues at $1.66-million

Executive Summary

• Else Nutrition reported a dramatic operational turnaround in Q3 2025, with gross margin expanding to 34% (up from –9% YoY) and operating expenses falling 68% year‑over‑year.
• Operating loss narrowed to $580k, while revenue held steady at $1.66 M despite temporary out‑of‑stock issues.
• Cash on hand was $91k and trade payables were reduced by 46% to $1.53 M, improving liquidity and debt‑management capacity.

Key Details

• Gross Profit Margin: 34% in Q3 2025 vs. –9% in Q3 2024 and –4% in Q2 2025.
• Operating Expenses: $1.15 M in Q3 2025 (down from $3.56 M in Q3 2024), a 68% YoY reduction.
• Operating Loss: $580,000 in Q3 2025 vs. $3.72 M loss in Q3 2024.
• Revenue: $1.66 M in Q3 2025 (slightly down from $1.79 M in Q3 2024).
• Cash Position: $91,000 at quarter‑end (includes restricted cash).
• Trade Payables: Decreased 46% to $1.53 M as of Sept. 30 2025 (from $2.84 M on Dec. 31 2024).
• Management Commentary: CEO Hamutal Yitzhak highlighted cost‑optimization, manufacturing transition, and progress toward profitability; noted ongoing regulatory modernization for U.S. infant formula and preparation for next clinical phase of plant‑based infant formula.
• Strategic Initiatives: Engaging international partners for commercial, R&D, and manufacturing collaborations; focusing on supply‑chain resolution, retail/online expansion, and regulatory milestones.
• Conference Call: Business update scheduled for Monday, Nov 17 2025 at 10:00 a.m. ET; dial‑in numbers provided, webcast replay available through Sept 17 2026, telephone replay by Dec 1 2025.

Notable Quotes

“We delivered a dramatic improvement in our fundamentals. Our gross margin expansion to 34 per cent and a 68‑per‑cent reduction in operating expenses demonstrate the effectiveness of our restructuring and cost‑control initiatives.” – Hamutal Yitzhak, CEO

Materiality Assessment: Material – Positive** (The release contains significant financial improvements and forward‑looking operational guidance.)